Literature DB >> 29117365

Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS.

Jeanie Kim1, Joseph S Ross1,2, Amy Kapczynski1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29117365     DOI： 10.1001/jama.2017.16477

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  Labeling Changes and Costs for Clinical Trials Performed Under the US Food and Drug Administration Pediatric Exclusivity Extension, 2007 to 2012.

Authors:  Michael S Sinha; Mehdi Najafzadeh; Elizabeth K Rajasingh; James Love; Aaron S Kesselheim
Journal:  JAMA Intern Med       Date:  2018-11-01       Impact factor: 21.873

Review 2.  Treatment of hyperphosphatemia: the dangers of high PTH levels.

Authors:  Justine Bacchetta
Journal:  Pediatr Nephrol       Date:  2019-11-06       Impact factor: 3.714

3.  Improved chondrogenic performance with protective tracheal design of Chitosan membrane surrounding 3D-printed trachea.

Authors:  Hyeonji Kim; Jae Yeon Lee; Hyeonseok Han; Won-Woo Cho; Hohyeon Han; Andrew Choi; Hyeonjun Hong; Jae Yun Kim; Jeong Hun Park; Sun Hwa Park; Sung Won Kim; Dong Sung Kim; Dong-Woo Cho
Journal:  Sci Rep       Date:  2021-04-29       Impact factor: 4.379

4.  Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency.

Authors:  Matthew Herder
Journal:  Milbank Q       Date:  2019-08-12       Impact factor: 4.911
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.